Overview of Cutaneous T-Cell Lymphomas

Hematol Oncol Clin North Am. 2019 Aug;33(4):669-686. doi: 10.1016/j.hoc.2019.04.004. Epub 2019 May 23.

Abstract

Non-Hodgkin's lymphoma (NHL) encompasses a diverse collection of systemic and primary cutaneous lymphomas. Cutaneous T-cell lymphomas (CTCLs) represent about 13% of all NHLs, which are further subdivided into a heterogeneous group with vastly different presentations and histologic features. Diagnosis requires integration of clinical, pathologic, and molecular features. Among CTCLs, mycosis fungoides and Sézary syndrome are the most prevalent. Treatment is aimed at limiting morbidity and halting disease progression. Hematopoietic stem cell transplantation is the only therapy with curative intent.

Keywords: Cutaneous T-cell lymphoma; Diagnosis; Genetics; Histology; Mycosis fungoides; Review; Sézary syndrome; Therapy.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Lymphoma, T-Cell, Cutaneous / classification
  • Lymphoma, T-Cell, Cutaneous / genetics
  • Lymphoma, T-Cell, Cutaneous / mortality
  • Lymphoma, T-Cell, Cutaneous / therapy*
  • Mycosis Fungoides / classification
  • Mycosis Fungoides / genetics
  • Mycosis Fungoides / mortality
  • Mycosis Fungoides / therapy
  • Progression-Free Survival
  • Sezary Syndrome / classification
  • Sezary Syndrome / genetics
  • Sezary Syndrome / mortality
  • Sezary Syndrome / therapy
  • Skin Neoplasms / classification
  • Skin Neoplasms / genetics
  • Skin Neoplasms / mortality
  • Skin Neoplasms / therapy*

Substances

  • Antineoplastic Agents